GlassScriptPhysician profile
James K Brown
NPI 1841274396
$3,885.18
in general payments reported to CMS, 2019-2025
30 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $377 · 2021: $15.60 · 2022: $14.89 · 2023: $262 · 2024: $777 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $494.02 | 2019-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $402.31 | 2022-2025 | Vraylar, Botox |
| Otsuka America Pharmaceutical, INC. | $366.31 | 2019-2024 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $340.55 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $290.31 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $265.07 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $204.73 | 2019-2025 | Trintellix |
| Lundbeck LLC | $144.51 | 2019-2025 | Rexulti |
| Allergan, INC. | $128.61 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $128.51 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $124.47 | 2019-2025 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.28 | 2024-2025 | Caplyta |
| Acadia Pharmaceuticals INC | $109.14 | 2020 | |
| Validus Pharmaceuticals LLC | $88.90 | 2023-2024 | Equetro |
| Vanda Pharmaceuticals INC. | $87.53 | 2019-2025 | Hetlioz, Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $78.89 | 2019 | |
| Neurocrine Biosciences, INC. | $77.89 | 2019-2025 | |
| Tris Pharma INC | $61.45 | 2019-2025 | Dyanavel Xr |
| Shire North American Group INC | $59.36 | 2019 | |
| Jazz Pharmaceuticals INC. | $51.22 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $46.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $42.64 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $40.10 | 2025 | Austedo Xr |
| Adlon Therapeutics L.P. | $36.42 | 2019 | |
| Corium, LLC | $21.90 | 2025 | Azstarys |
| Noven Therapeutics, LLC | $16.40 | 2024 | Xelstrym |
| Brainsway USA INC | $15.81 | 2024 | Brainsway Deep Tms System |
| Idorsia Pharmaceuticals US INC | $14.98 | 2023 | Quviviq |
| Almatica Pharma LLC | $14.07 | 2023 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.